Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

GROUNDWORK BIOAG NAMED THIRD MOST INNOVATIVE FOOD COMPANY IN THE WORLD BY FAST COMPANY

Groundwork BioAg

Groundwork BioAg® has been selected by Fast Company as one of the World’s Most Innovative Food Companies for 2022. The bioagriculture company was recognized for tackling grand challenges facing humankind today: food security, soil health and climate change. Groundwork BioAg ensures farmers have access to its cost-effective mycorrhizal inoculants that increase yield while reducing the use of phosphorus, protecting against drought and permanently sequestering carbon. The company’s Rootella® product line sets the standard for quality, concentration and predictability through its mass production technology innovation. This translates to greater in-field performance to help farmers grow more productive and resilient crops. “We are honored to stand with this prestigious group of companies recognized by Fast Company for innovation that is transforming the world today,” said Dr. Yossi Kofman, CEO and Co-Founder, Groundwork BioAg. "As commercial agriculture reconciles societal shifts and climate change realities, the industry is adopting more regenerative practices that reduce farmers’ dependence on toxic and expensive chemical fertilizers. For the health of our planet and all who live here, we remain committed to restoring the world’s soils with the mainstream application of mycorrhizae – the Queen of Biologicals.” Applied on more than one million acres in 2021, Groundwork BioAg accelerated global production and expanded product formulations and application methods. Previously, the biotechnology and manufacturing processes were too complex and costly to produce a highly effective and affordable inoculant for mainstream agriculture. “The industrial agriculture revolution only took society so far and its potential has been exhausted. Groundwork BioAg’s innovations are at the epicenter of the next agricultural revolution — the bioagricultural revolution — and it will grow, as healthy plants do, from soil rich in mycorrhizae,” said Kofman. As part of its annual process, Fast Company ’s editors and writers sought out the most groundbreaking businesses across the globe and industries. The World’s Most Innovative Companies is Fast Company ’s signature franchise and provides both a snapshot and a roadmap for the future of innovation across the most dynamic sectors of the global economy. “The world’s most innovative companies play an essential role in addressing the most pressing issues facing society, whether they’re fighting climate change by spurring decarbonization efforts, ameliorating the strain on supply chains, or helping us reconnect with one another over shared passions,” said Fast Company Deputy Editor David Lidsky. Fast Company ’s Most Innovative Companies issue (March/April 2022) is available online and on newsstands beginning March 15. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of mainstream agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

March 09, 2022 07:30 AM Central Standard Time

MyYogaTeacher Launches Official 200-Hour Yoga Teacher Training Program Online

MyYogaTeacher

MyYogaTeacher announces the launch of a 200-hour Yoga Teacher Training (YTT) program, which will be offered three times each year, and features live instruction by a group of highly-skilled, certified, India-based and -trained instructors. Unlike the self-paced, pre-recorded, video-based packages sold online, which offer digital materials, videos, and only a handful of live sessions led by an instructor, MyYogaTeacher’s courses are 100% live, taking place daily over a period of 95+ days. MyYogaTeacher was named one of “The 6 Best Online Yoga Classes of 2022” by Byrdie. “Our students have a wide range of reasons for pursuing teacher training,” says Jitendra Gupta, the Indian-born CEO of MyYogaTeacher, who co-founded the company with Mexican-American entrepreneur Will Allen, after pursuing yoga to improve his personal physical and mental well-being. “Some definitely have a desire to teach yoga, but others simply want to improve their practice and challenge themselves a bit further by expanding their yogic knowledge and taking their physical practice to the next level.” The program is open to students of all levels. The Yoga Alliance-certified teacher training program features 6 highly-qualified MyYogaTeacher instructors, and is led by Rohan Shroff, who earned a Masters in Science in Yoga from SVYASA University in Bangalore and has over 1300 hours of yoga teacher training from well-known and respected institutions in India. Rohan has graduated over 500 students from online and in-person teacher training programs, including over 100 MyYogaTeacher students, and he also teaches Pranayama, Meditation, Ashtanga Vinyasa, Yoga Sutras, and Methodology, at MyYogaTeacher. Besides live instruction on a variety of topics–yoga history, theory, anatomy and physiology–in addition to asana practice, pranayama, chanting, meditation, yoga sutras, and more, the program includes a 150-page e-book, recordings of the classes so students can return to each session and review, plus a community setting that keeps students engaged, motivated and energize. They can also live chat with instructors (Bodhi Abishek Singh, Gomati Woli, Stuti Asher, Umesh Balavaradaraju, Bharath Ram) and fellow students. “What’s great is that your investment in teacher training is nowhere close to the cost you will incur by traveling to India during our post-Covid era,” says Gupta. “And we offer students a 14-day free trial so if they are not happy with the coursework, they can cancel.” The first round of this YTT program runs from March 5 to May 28, and the program will be offered 3 times each year. The next round will take place in the summer of 2022. Learn more about the program and featured instructors here. About MyYogaTeacher MyYogaTeacher is reconnecting yoga to its roots and sharing it through live lessons taught by the world’s foremost teachers who studied yoga at India’s most elite universities and schools. With over 100,000 registered U.S. students, it offers over 40 group classes daily, and provides private sessions, along with over one million minutes of live interactions each month. The Cupertino, California-based company was co-founded in 2018 by Jitendra Gupta and Will Allen. Gupta is the successful former co-founder of Punchh, who turned his struggle with burnout into a platform to help others. Allen is a former mechanical engineer who left the lucrative aerospace industry to travel the world, and pursue yoga and meditation over the past decade. MyYogaTeacher recently received $3 million in seed round funding, led by TSVC, with participation from Leonis Investissement, Weekend Fund, All Access Fund, and Bertelsmann Digital Media Investments. For more information, visit MyYogaTeacher.com. Contact Details Carolyn Kamii PR Carolyn Kamii +1 310-251-0550 carolyn@carolynkamii.com Company Website https://www.myyogateacher.com/

March 09, 2022 04:30 AM Pacific Standard Time

Fine Hygienic Holding recognized as one of few Global Top Employers for the first time

Fine Hygienic Holding

In recognition of its excellent work environment, Fine Hygienic Holding (FHH), the world leading wellness group and manufacturer of hygienic paper products and long-lasting germ protection solutions, has been recognized as a global Top Employer for 2022 by the prestigious Top Employers Institute. FHH was named Top Employer Middle East 2022, as one of few employers worldwide recognized at the awards for its outstanding human resources strategy as well as employees’ experience and culture. The group’s operations in Egypt, Jordan, KSA and the UAE all achieved the highest global benchmark of HR practices which cover the areas of People Strategy, Work Environment, Talent Acquisition, Learning and Development, Well-being and Diversity & Inclusion. Marking the group’s latest achievement, James Michael Lafferty, FHH’s CEO, said, “We are very proud of being recognized as a top employer in the field of FMCG. Attaining this certificate proves yet again that our motto – if we take care of our people, the business will take care of itself – is being put into action every single day. We know that our success as a company derives from the strength of our most important asset, our Fine people. That is why we are constantly working to create an environment that attracts and retains the very best, and always celebrate employees who excel both in their performance and in embodying our company values.” Fine Hygienic Holding has around 3,000 employees from more than 40 nationalities spread among its operations in the MENA region with two headquarters: Amman and Dubai. To achieve the “Top Employer” award, the company went through a multi-stage certification program. Companies from all over the world wishing to participate in the award are required to fill a detailed survey covering six HR domains consisting of 20 topics and undergo extensive auditing for each HR process. The Top Employers Institute specializes in the alignment of practices and policies through a global program based on benchmarking best HR practices to grant the global workforce with full outstanding people practices. About Fine Hygienic Holding: Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple accolated and awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit │ Corporate Communication & PR Director Rkawalit@finehh.com Company Website https://www.finehh.com/

March 08, 2022 11:24 PM Eastern Standard Time

Image

Data from pre-clinical study of OCT461201 shows positive results

Oxford Cannabinoid Technologies Holdings Plc

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased to announce positive results from a pre-clinical pain study for its lead compound, OCT461201, targeting the global Chemotherapy Induced Peripheral Neuropathy (“CIPN”) treatment market valued at US$1.61bn in 2020 and forecasted to reach US$2.37bn by the year 2027. CIPN is a peripheral neuropathy resulting from the neurotoxic effects of common chemotherapeutic drugs. The hallmarks of CIPN are pain, numbness and tingling in the extremities. On average, an estimated 60 per cent. of people undergoing chemotherapy are affected by CIPN at 3 months. CIPN can be progressive and enduring, leading to years of debilitation and suffering. The results from OCTP’s recent study show that OCT461201 successfully reduces pain in a pre-clinical animal model of CIPN induced by paclitaxel, a widely used chemotherapy agent. Two common symptoms of CIPN are pain caused by innocuous stimuli, like light touch (mechanical allodynia) and heat or cold (thermal hyperalgesia). In the study, OCT461201 significantly reduced pain from both mechanical allodynia and thermal hyperalgesia compared to untreated animals. Globally, there is an urgent need for new therapies to treat CIPN as there are currently no approved therapies for this condition. The current standard of care is the off-label use of gabapentinoids (gabapentin and pregabalin) and antidepressants (e.g. duloxetine), drugs associated with serious side effects. Furthermore, in some cases their overall clinical effectiveness is inadequate, leaving cancer patients in pain, with a reduced quality of life and the prospect of having to change or stop their chemotherapy altogether. Commenting on the results of the experiment, OCTP Chief Executive John Lucas said: “To obtain such a positive result in this study is significant and provides further evidence that OCT461201 could be an effective therapy in the treatment of CIPN in cancer patients. Based on previously completed pre-clinical safety experiments, the Directors believe the administered dose of OCT461201 could have been increased by over three times. The results of this study demonstrate the opportunities open to OCT461201 in treating a major and common side effect experienced by so many cancer patients and we are more excited than ever to be starting phase 1 clinical trials early next year. These latest results reaffirm the potential of OCT461201 across multiple indications.” Oxford Cannabinoid Technologies Holdings plc is the holding company of Oxford Cannabinoid Technologies Ltd, a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market (together the “Group”). Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.The Group’s portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group’s lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical testing and development with clinical trials scheduled for Q1 2023. The Group’s product pipeline also uses a balanced drug product strategy that employs both natural and synthetic compounds for the treatment of rare diseases and includes chemically modified phytocannabinoids with improved drug-like characteristics and a proprietary library of cannabinoids. OCTP operates a partnership model with external academic and commercial partners. Caution regarding forward looking statementsCertain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. Contact Details Harbor Access Jonathan Paterson +1 475-477-9401 jonathan.paterson@harbor-access.com Investor Relations Ricahrd Leighton +1 475-477-9403 Richard.Leighton@Harbor-Access.com Company Website https://www.oxcantech.com/

March 08, 2022 03:26 PM Eastern Standard Time

Video

Industrial Defender Opens European Office in the Netherlands to Meet Increasing Global Demand for OT Cybersecurity

Industrial Defender

Industrial Defender, the leader in OT cybersecurity, today announced its expansion into Europe to meet increasing demands for industrial security in the region. Their new office, located in the Netherlands, will service a variety of critical industries across the entire EMEA region, including utilities, oil & gas, manufacturing, rail, maritime and water companies. “The desire for OT cybersecurity solutions in Europe has grown tremendously over the past few years, and we’re committed to providing a local team on the ground to meet this increasing demand,” said Dario Lobozzo, Managing Director EMEA. “This expansion ensures that our growing customer base in the region has access to the resources they need to run a successful ICS cybersecurity program.” As part of its effort to help European companies reach their highest level of cyber resilience possible during this time of escalating cyberthreats, Industrial Defender is offering critical infrastructure companies in region a complimentary OT cybersecurity strategy review through the end of March. The company is also actively hiring additional cybersecurity professionals in Europe. Interested candidates can explore open positions here: https://www.industrialdefender.com/careers/ To learn more about Industrial Defender’s European presence or to request a complimentary OT cybersecurity strategy review, reach out at https://www.industrialdefender.com/speak-with-an-ot-security-architect/. About Industrial Defender Since 2006, Industrial Defender has been solving the challenge of safely collecting, monitoring, and managing OT asset data at scale, while providing cross-functional teams with a unified view of security. Their specialized solution is tailored to complex industrial control system environments by engineers with decades of hands-on OT experience. Easy integrations into the broader security and enterprise ecosystem empower IT teams with the same visibility, access, and situational awareness that they’re accustomed to on corporate networks. Learn more at www.industrialdefender.com. Contact Details Industrial Defender Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

March 08, 2022 09:00 AM Eastern Standard Time

Cardiology Consultants of Philadelphia Launches Heart Disease Prevention Campaign

Cardiology Consultants of Philadelphia (CCP)

Cardiology Consultants of Philadelphia (CCP) — the region’s largest and most extensive cardiology practice — has launched a state-of-the-art heart disease prevention program — the CB4 Prevention Program. The practice has locations at more than 36 offices in five counties, making it uniquely qualified to reach and potentially save the highest number of patients possible. CCP has over 100 cardiologists on staff who are experts across all specialties. Each physician on the team offers comprehensive cardiovascular care and education based on the latest research, and uses cutting-edge, innovative technology to treat and diagnose cardiovascular diseases. Patients looking to identify their risk factors and take preventive action against heart disease will have access to advance testing as needed, as well as an individualized program based off of the initial consultation with a doctor through CB4. “Preventative care is an incredibly important first step for patients to take, as heart disease is easier to prevent than it is to treat,” said Dean Karalis, MD, FACC, FNLA, a CCP physician. “CB4 is about awareness as much as it is about heart disease prevention—success requires us to create a highly-individualized, ongoing program for each patient based on a number of factors including risk factors and family history.” As part of the prevention evaluation, the patient will have blood work drawn to screen for high cholesterol as well as other cardiovascular risk factors. The lab work will include a comprehensive metabolic panel and a Hemoglobin A1c Test (diabetes screener). The results of the bloodwork will give one of the practice’s 11 CB4 cardiologists — all of whom are preventative-trained and focused cardiologists — clear insight to develop a plan of action from a preventative angle. The CB4 Prevention Program can be scheduled through any of the CCP offices in the Philadelphia region. Appointments are available in person or virtually. About Cardiology Consultants of Philadelphia CCP is affiliated with virtually every major hospital in the region and serves patients from over 36 offices in all five Southeastern Pennsylvania counties. Contact Details Lauren Stralo +1 484-747-0172 lstralo@levlane.com Company Website https://ccpdocs.com/

March 08, 2022 08:53 AM Eastern Standard Time

Q-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass

Q-Vant Biosciences

Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed an agreement with In vitro Plant-tech AB, a Swedish plant cell cultivation company whose technology platform and manufacturing facilities will permit the sustainable production of Quillaja saponaria biomass within bioreactors. This collaboration will create an additional source of raw materials that will enhance the sourcing matrix of Q-VANT, adding the key benefit of flexibility of being able to produce it anywhere in the world. This is in line with the company’s strategy of guaranteeing the long-term sustainability and continuity of supply for saponin-based adjuvants including QS-21 for the pharmaceutical markets. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune response to vaccine antigens and is a vital component in more than 17 human vaccine candidates, including the FDA-approved GSK Shingrix® shingles vaccine and the WHO-authorized, GSK Mosquirix® malaria vaccine. In addition, saponin-based adjuvants are a key component in the Novavax COVID-19 vaccine, which has been shown to be highly effective in clinical trials and has recently been authorized for emergency use by the European Union (EU) and the World Health Organization (WHO). QS-21 is traditionally extracted from the bark of mature trees native to Chile known as the Quillaja saponaria — a harvesting process that negatively impacts the forest and the sustainability of the resource. Today, with regulatory restrictions on deforestation of this tree, and projected demand for QS-21 in the billions of doses annually, shortages of QS-21 are affecting the pharmaceutical market’s ability to meet the surging need for vaccine dosages globally. Q-VANT’s Q-SAP™ (Quillaja Sustainable Adjuvant Platform) is a technology platform combining computational learning techniques and a proprietary multi-step purification process to systematically enhance Quillaja sourcing options and to drive extremely effective outputs. The first of its kind, Q-SAP enables Q-VANT to obtain adjuvant products from a wide range of Quillaja-based plant materials, which can increase production volumes by as much as 1,000 times, leading to billions of doses in a 100% sustainable way. “ In vitro Plant-tech’s plant cell technology experts have over 25 years of experience,” said Doug Klaiber, the CEO of Q-VANT. “Their expertise coupled with their cell culture platform and production capabilities will enhance our supply and is complementary to our mission to meet the growing demand and secure supply chain continuity for delivering the world with billions of doses of 100% sustainable QS-21 and other saponin-based adjuvants.” “ In vitro Plant-tech is delighted to offer our plant cell cultivation technology, cell cultivation and enhancement platforms, and production capabilities to support Q-VANT on their mission to meet the growing demand for QS-21 and other saponin-based adjuvants,” said Anna Holefors, founder and CEO of In Vitro Plant-tech. “We look forward to paving the path for a fully sustainable QS-21 production platform and helping in the development and production of life saving vaccines.” About In vitro Plant-tech: In vitro Plant-tech is a research derived company, specializing in development and production of innovative active ingredients using the plant cell cultivation (PCC) technology. This technology enables sustainable production of uniform, customised, high quality plant material. As experts within PCC, we have developed a metabolic enhancement technology (MET) platform which enables optimised production and accumulation of bioactive substances. The company's products are used in the pharmaceutical, cosmetic, and food industries. The company also provides contract biomanufacturing and production services. For more information, visit www.invitroplanttech.se. About Q-VANT Biosciences Q-VANT is a privately held biosciences company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company’s next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 times – enabling the production of billions of doses annually to meet today’s increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Contact Details Erin O'Brien +1 401-490-9700 erin.obrien@svmpr.com Company Website https://q-vant.com/

March 08, 2022 07:00 AM Eastern Standard Time

Electronic Caregiver Presents Next Generation of Remote Patient Monitoring Technology With Virtual Caregiver at 2022 HIMSS Global Health Conference

Electronic Caregiver

Electronic Caregiver, a national digital health technology and services company, will debut Addison, the Virtual Caregiver, at the 2022 HIMSS Global Health Conference in Orlando, Florida, March 14-18. Addison is the next generation of remote patient monitoring (RPM) technology and offers a solution to the global caregiver crisis and the ongoing COVID-19 challenges by providing health care management outside the doctor’s four walls. Addison, anticipated to be released later this year, is a state-of-the-art, 3D-animated caregiver with an endearing personality. The Virtual Caregiver is designed to engage with and help monitor the health of aging and chronically ill clients, as well as child patients via touch-screen devices strategically placed throughout a residence. “Addison is a revolutionary new tool for use by providers to optimize patient care – monitoring, increasing treatment adherence, and improving health outcomes,” said Electronic Caregiver CEO Anthony Dohrmann. “Whether a patient with one or more morbidities requires assistance at home to follow complex medication regimens, comply with physical therapy, monitor vitals, or requires increased support for managing behavioral health conditions, Addison has the capabilities to extend care from provider to home.” Powered by Amazon Web Services (AWS) and Intel, Addison helps monitor patients’ health by providing voice-driven medication reminders, ensuring patients are following their doctor’s treatment plans, and offering 24/7 emergency response and telehealth services. Addison can also lead patients through the steps of recording a vital, such as blood pressure, oxygen saturation levels, and temperature, with the ability to share that information with designated providers and caregivers in real time. Addison gives a face and personality to the RPM experience. The Virtual Caregiver can also be customized to fit users’ preferences. Clients can choose from eight avatars of different ethnicities and genders to interact with, and Addison’s environment can mirror client lighting and weather automatically. Electronic Caregiver will present Addison, the Virtual Caregiver, in addition to its other RPM technology alongside Care Management company MD Revolution, Inc. at HIMSS Booth 4109. In 2020, Electronic Caregiver formed a partnership with MD Revolution, a provider of full-suite RPM and Chronic Care Management (CCM) solutions, to provide health practices with the technology and services to monitor patients remotely. “Through our highly productive partnership, we’re already delivering a 21st century health care experience for thousands of patients, and we’re confident our joint capabilities will scale to all the innovative health care providers in America,” said Kyle Williams, CEO of MD Revolution. “Our common goals are clear: to create more health care delivery capacity and to drive better patient outcomes. I’m confident we will continue to augment the traditional medical practice by building trust one patient at a time, one provider at a time.” MD Revolution offers Electronic Caregiver’s Pro Health, a 24/7 chronic care and monitoring system, as its preferred RPM device. The Pro Health includes a cellular-based console for the home and wearable wrist pendant for care support on the go. Like Addison, the Pro Health offers emergency response and health care management and can be paired with a multitude of Bluetooth devices to track vitals in real time. Devices are ordered, provisioned, and shipped directly to patients, with no up-front cost and no long-term commitment to the practice. MD Revolution has integrated the Pro Health into its HIPAA-compliant digital care management platform, called RevUp, which will be showcased during HIMSS. RevUp allows patient information to be securely monitored by a licensed care coordination team working as an extension of the provider practice. RevUp data is available with seamless, universal integration into the electronic health record (EHR), allowing for more proactive care by leveraging objective data and trend analysis. The solution also includes integrated care documentation, automated claims creation, and full-service marketing and enrollment services – resulting in more enrollments and faster reimbursement. Together, Electronic Caregiver and MD Revolution provide better outcomes, improved adherence, and simplified compliance management through sustainable telecare optimized for scale, economics, and services. Utilizing Electronic Caregiver’s technology, MD Revolution’s RevUp platform makes RPM implementation easy, supporting providers through the evolution of their practice. RevUp merges technology with traditional healthcare, seamlessly integrating with a provider’s day-to-day while upholding their practice's long-standing values. “We are reducing the number of office visits, ER visits, urgent care visits. So, the volume to medical facilities will very likely be reduced because we can monitor patients at home,” said MD Revolution client Dr. Edward Wingfield of Hamilton Cardiology Associates in New Jersey. “A lot of times, we bring patients in to just get a blood pressure or just to get a weight to make sure they are not going into heart failure. If all these things can be done remotely and we can act on it, it will cut medical costs.” About Electronic Caregiver Electronic Caregiver is a privately held digital health technology and services company headquartered in Las Cruces, NM (USA). ECG's mission is to design and deliver innovative, impactful telehealth products and services that bridge the chasm between the doctor's office and the patient's home to improve outcomes, expand access, and optimize resource allocation. ECG has been qualified as a technology solution provider in the Amazon Partner Network (APN). The company's solutions are available through health care organizations, physician practices, care management firms, home care agencies, and senior housing providers. www.electroniccaregiver.com About MD Revolution, Inc. MD Revolution, Inc. is an innovative Care Management company uniquely combining technology, services, and analytics to produce scalable, high-touch care models that enrich the patient-provider experience, improve the health of millions of patients, and enhance the profitable, effective practice of medicine for thousands of providers. MD Revolution’s remote care programs mitigate the challenges associated with meeting the requirements for Medicare’s Chronic Care Management (CCM), Remote Patient Monitoring (RPM), RPM for RHC/FQHC’s, Behavioral Health Integration (BHI), Annual Wellness Visits (AWV) and population health programs. Solutions are available as turn-key solutions, software-as-a-service, and through reseller partners. www.mdrevolution.com Contact Details Stephanie Guadian, Director of Public Relations +1 575-649-4604 sguadian@ecg-hq.com Alexia Severson, Public Relations Associate +1 575-993-9612 aseverson@ecg-hq.com

March 03, 2022 01:27 PM Mountain Standard Time

Image

Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) from the Israeli Innovation Authority

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant from the Israel Innovation Authority (IIA) for a total budget of NIS 10 million ($3.1 million) and a net grant of NIS 4 million ($1.25 million). The grant will support the Company’s FDA IND enabling studies For its next clinical trial in ALS patients The funds will be used to advance the filing of an IND with the FDA by the end of 2022, to secure the approval of the FDA of the anticipated Phase IIa, US, multicenter, clinical trial protocol of AstroRx® for the treatment of ALS and expand the use of AstroRx® cell product for other neurological conditions such as multiple sclerosis and glaucoma. Kadimastem CEO Asaf Shiloni said, "This grant is an important expression of trust by the Israeli Innovation Authority in Kadimastem and the potential of our clinical, cell therapy platform to provide millions of patients worldwide with life-saving treatments. The Company is currently in one of the most significant periods in its history, both clinically and financially. We are scaling-up for a Phase IIa clinical trial of AstroRx® for ALS in the US as well as preparing to list on NASDAQ. This grant provides us with the necessary resources to advance both sets of plans.” Prof. Michel Revel, Chief Scientist of Kadimastem: "We thank the Innovation Authority for supporting Kadimastem, its work and its vision." This is the second grant awarded to Kadimastem in the past months by the IIA. The previous grant was earmarked for the scale-up of the production of AstroRx® as well as for creating a frozen, off-the-shelf product, to ensure the clinical quality of the product for patients worldwide. In 2019, Kadimastem completed a first-of-its-kind, Phase I/IIa clinical trial of AstroRx®, whereby the treatment was injected into the spinal cord fluid of 10 patients in a standard lumbar puncture procedure. AstroRx® showed high safety profile and significantly slowed the rate of disease progression for 3 months following treatment, as measured by the ALSFRS-R. Dr. Michal lzrael, VP of R&D said, “The grants the Company has received from the IIA for the development and clinical production of Kadimastem’s cellular, off-the-shelf AstroRx® product are a clear recognition of the company's innovative technology. Astrocytes, the support cells in the nervous system, which are the basis for the AstroRx® product, have enormous therapeutic potential to protect all types of nerve cells. We are working hard to bring a product to market that will help to improve the lives of ALS patients worldwide as well as to development this therapy for other neurodegenerative diseases such as multiple sclerosis and glaucoma." About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

March 03, 2022 08:05 AM Eastern Standard Time

Image

1 ... 192 193 194 195 196 ... 249